Page results
-
UCLH Private Healthcare: world-class consultants, advanced treatments, and personalised care in central London.
-
Information supporting adults affected by cancer and blood conditions being treated at UCLH.
-
UCLH has been selected as the lead site in Great Britain for Neuralink’s GB-PRIME study, a clinical investigation for Neuralink’s brain-computer interface (BCI).
-
This page has been written by the Neuropsychiatry Department at the National Hospital for Neurology and Neurosurgery. The aim of this page is to provide general information about the procedure called Repetitive Transcranial Magnetic Stimulation (rTMS).
-
This information has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the oesophagus (gullet).
-
This page has been written for patients who have been referred for High Dose Rate (HDR) brachytherapy to the bronchus
-
Easy read information for patients living with a catheter.
-
This patient information includes different relaxation techniques which patients being seen by the Post-COVID Service team may find useful.
-
Patient information leaflet for patients suffering form long COVID who are experiencing breathlessness or changes in their breathing pattern.
-
This provides information about a treatment for uterine fibroids known as ‘transcervical ultrasound-guided radiofrequency ablation’. You may also hear it called by the Manufacturer’s name ‘Sonata®’ for short.
File results
-
FOI/2023/0542 - Pulmonary rehabilitation (PR)
-
FOI/2023/0550 - Varicose veins referrals, treatment and wait time
-
FOI/2023/0553 - Maternity complaints by ethnicity
-
FOI/2023/0559 - Patients admitted to hospital with dental distress
-
FOI/2023/0560 - Digital maternity training platform
-
FOI/2023/0561 - Birthrate Plus
-
FOI/2023/0563 - Treatment for Haemophilia B and Von Willebrand disease
-
FOI/2023/0565 - Rare diseases - diagnosis/ treatment for Fabry/ Gaucher/ Pompe
-
FOI/2023/0566 - Structure chart for IM &T, Business Intelligence, Informatics
-
FOI/2023/0569 - Treatment for Ruxolitinib